机译:alectinib用于患有ALK重排阳性非小细胞肺癌的患者及性能状况不佳(九州肺部肿瘤组织?1401)
Research Institute for Diseases of the Chest Graduate School of Medical Sciences Kyushu University;
Department of Thoracic Oncology National Cancer Center Hospital;
Division of Thoracic Oncology Shizuoka Cancer Center;
Research Institute for Diseases of the Chest Graduate School of Medical Sciences Kyushu University;
Department of Respiratory Medicine Kumamoto Regional Medical Center;
Department of Clinical Oncology Tokyo Medical and Dental University;
Department of Respiratory Medicine Iwate Prefectural Central Hospital;
Department of Respiratory Medicine Steel Memorial Yawata Hospital;
Department of Respiratory Medicine National Hospital Organization Asahikawa Medical Center;
Department of Pulmonary Medicine and Oncology Graduate School of Medicine Nippon Medical School;
Department of Respiratory Medicine Japanese Red Cross Okayama Hospital;
Department of Respiratory Medicine Kesen-numa City Hospital;
Division of Respiratory Medicine Ishikawa Prefectural Central Hospital;
Third Department of Internal Medicine Wakayama Medical University;
Department of Thoracic Medical Oncology Oita Prefectural Hospital;
Department of Respiratory Medicine Fukuoka University Chikushi Hospital;
Clinical Research Support Center Kyushu;
Medical Information Center Kyushu University Hospital;
Division of Clinical Pharmacology and Translational Research Exploratory Oncology Research and;
Third Department of Internal Medicine Wakayama Medical University;
Research Institute for Diseases of the Chest Graduate School of Medical Sciences Kyushu University;
Department of Thoracic and Breast Surgery Oita University;
Research Institute for Diseases of the Chest Graduate School of Medical Sciences Kyushu University;
Alectinib; Poor performance status; ALK rearrangement; NSCLC; Pharmacokinetics;
机译:ALK重排阳性非小细胞肺癌患者的存活分析及邻接治疗的性能状况不佳:九州肺肿瘤学群体的更新结果
机译:alectinib用于患有ALK重排阳性非小细胞肺癌的患者及性能状况不佳(九州肺部肿瘤组织?1401)
机译:P1.03-004 alectinib适用于ALK重排阳性非小细胞肺癌的患者和绩效状况不佳
机译:使用有效的体内技术(Gilupi Cellcollector
机译:ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
机译:ALK重排阳性非小细胞肺癌患者的生存率分析并用艾来替尼治疗的病情较差:九州1401年肺癌研究组的最新结果
机译:ALK重排的肺癌患者对依乐替尼的严重反应